FREE TRIAL - NO CARD NEEDED
Pubrio gives your team the data, timing, and tools to reach the right prospects before the competition does.
Company & people search
Filter 560M+ contacts by role, industry, tech stack & more.
Sequences
Automate multi-step outreach without losing the personal touch.
Market signals
Stay ahead of every market shift. Pubrio Signals watches companies for you and delivers the right intelligence.
Start your free trial
Join 9,000+ revenue teams already using Pubrio.
No credit card · Cancel anytime · GDPR safe
Already have an account?Log in
United States · Research
Research
Pharmaceuticals
Healthcare
Biotechnology Research
Angiex is a biotech company focused on developing novel Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to target the hallmarks of cancer lethality. Their Nuclear Delivery Platform™ aims to deliver chemotherapeutic payloads to the nucleus of tumor cells and endothelial cells of tumor blood vessels, offering potential for exceptional efficacy and therapeutic margin in solid cancer treatments. Angiex’s lead asset, AGX101, is a novel TM4SF1-directed ADC for the treatment of solid tumors, with a pipeline of additional ND-ADCs in development.
2015
Founded
Research
Industry
United States
Location
6,263,508
Ranking
10 employees
Size
Get full access to view complete information
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© Pubrio 2026
